Association of anti-hyperuricemia treatment and prevalent cardiovascular disease in hypertensive patients

Fanfang Zeng, Rong Huang, Yongkang Lu, Zhiye Wu, Lili Wang

Department of Cardiology, FuWai Hospital Chinese Academic of Medical Science, Shenzhen, Guangdong, China

Submitted: 21 January 2019
Accepted: 5 March 2019

Arch Med Sci 2020; 16 (3): 545–550
DOI: https://doi.org/10.5114/aoms.2019.84397
Copyright © 2019 Termedia & Banach

Abstract

Introduction: The current study aimed to evaluate the association of anti-hyperuricemia treatment and prevalent cardiovascular disease (CVD) in hypertensive patients.

Material and methods: Primary hypertensive patients with hyperuricemia were enrolled. All participants were separated into two groups: anti-hyperuricemia and control groups (without anti-hyperuricemia treatment). Comparisons of prevalent CVD including coronary heart disease, ischemic stroke and heart failure were made and the associations of anti-hyperuricemia treatment and prevalent CVD were analyzed.

Results: Compared to the anti-hyperuricemia group, patients in the control group had significantly higher serum C-reactive protein (10.6 ±2.8 vs. 7.4 ±1.2 mg/dl) and uric acid (UA) levels (438 ±33 vs. 379 ±64 μmol/l), and were more likely to receive β-blockers (34.2% vs. 31.1%) and calcium channel blockers (49.2% vs. 43.4%). The prevalence of ischemic stroke was higher in the control group (15.8% vs. 11.3%). Compared to other groups, blood pressure was significantly higher in patients in the 4 th quartile serum UA level group. In the unadjusted model, anti-hyperuricemia treatment was significantly associated with a reduced odds ratio (OR) of composite CVD. After adjusting for potential covariates, OR of anti-hyperuricemia treatment for composite CVD was 0.89 with a 95% confidence interval (CI) of 0.82–0.98. Associations of anti-hyperuricemia treatment and ischemic stroke were also significant with OR = 0.93 and 95% CI: 0.88–0.99, while associations of anti-hyperuricemia with coronary heart disease and heart failure attenuated into insignificance after adjusting for covariates.

Conclusions: In hypertensive patients with hyperuricemia, anti-hyperuricemia treatment was associated with lower odds of prevalent CVD.

Key words: hypertension, hyperuricemia, cardiovascular disease.

Introduction

Hypertension is a major risk factor for a variety of cardiovascular diseases (CVD) including coronary heart disease, ischemic stroke and heart failure [1–5]. Multiple clinical trials and meta-analyses have demonstrated that reducing blood pressure (BP) with medications reduces the risk of cardiovascular events [6–8].

Interestingly and importantly, epidemiological studies have shown that patients with hypertension are more likely to have hyperuricemia...
and the underlying mechanisms are multifactorial and are not fully understood yet [4, 9, 10]. Furthermore, prior studies have consistently shown that hypertensive patients with hyperuricemia had higher CVD risk than hypertensive patients with normal serum uric acid (UA) level [11–14]. Notably, allopurinol is commonly used to decrease serum UA level and prevent gout [15]. Through inhibiting xanthine oxidase, allopurinol reduces UA production. In addition, prior studies have shown that increased UA is associated with reduced nitric oxide generation and allopurinol may improve endothelial function and increase nitric oxide generation, which in turn reduce BP [15]. Indeed, prior some studies showed that lowering serum UA level with allopurinol was associated with BP reduction [10, 16]. However, to our knowledge, no randomized controlled trials have been conducted to evaluate whether treatment of hyperuricemia is beneficial for reducing BP as well as decreasing cardiovascular events in hypertensive patients with hyperuricemia.

Therefore, we conducted a cross-sectional study and the aim of this study was twofold: 1) to compare prevalent composite CVD including coronary heart disease, ischemic stroke and heart failure between patients with and without anti-hyperuricemia treatment; 2) to evaluate the associations of anti-hyperuricemia treatment and prevalent composite CVD. We believe that the results from this study can provide more evidence to support randomized controlled trials to evaluate whether treatment of hyperuricemia can reduce cardiovascular events in hypertensive patients in the future.

Material and methods

Study design and participants’ enrollment

This was a cross-sectional study and was approved by the Clinical Research Ethic Committee of FuWai Hospital Chinese Academy of Medical Science, Shenzhen, Guangdong, China. All participants were enrolled after informed consent was obtained and all participants were enrolled from FuWai Hospital Chinese Academy of Medical Science, Shenzhen, Guangdong, China. The inclusion criteria were as follows: documented primary hypertension, documented hyperuricemia or treatment with allopurinol for at least 3 months before enrollment. The exclusion criteria were as follows: documented secondary hypertension, or had acute gout flare in the last 3 months, treatment with anti-hyperuricemia medications other than allopurinol, had myocardial infarction, ischemic or hemorrhagic stroke or exacerbated congestive heart failure in the last 6 months, or had abnormal thyroid function (including both hypothyroidism and hyperthyroidism) and glomerular filtration rate (GFR) < 60 ml/min/1.73 m².

Baseline characteristics collection

Demographic characteristics (age and gender), smoking status, body mass index and documented comorbidities were collected at baseline by two independent investigators. Fasting venous blood was drawn for assessment of serum UA, fasting blood glucose (FBG), total cholesterol (TC), C-reactive protein (CRP) and creatinine levels. Specifically, all these measurements were conducted in the Cardiovascular Central Laboratory using biochemical methods with commercial kits. Serum creatinine level were used to calculate GFR using the Modification of Diet in Renal Disease (MDRD) formula [17]. Current medications used were collected. The dose of allopurinol used in the current study was between 100 mg and 300 mg/daily.

Blood pressure measurement and hypertension definition

Regarding the new ACC/AHA hypertension guideline [18], the definition of hypertension in this study was systolic blood pressure (SBP) ≥ 130 mm Hg and/or diastolic blood pressure (DBP) ≥ 80 mm Hg, and pulse pressure (PP) was calculated as SBP minus DBP. No smoking or caffeine-containing beverage consumption, or use of anti-hypertensive medication was allowed before BP measurement. Patients sat quietly for 15 min with their back supported and the appropriate cuff size was used with the bladder encircling at least 80% of the non-dominant arm (Omron HEM- BP742N 5 series, Tokyo, Japan). The patient’s arm was placed on the desk parallel to the heart level. Three readings with a 1-minute interval between measurements were performed and the last two readings were averaged as BP.

Statistical analysis

All patients were separated into two groups as anti-hyperuricemia and control (without anti-hyperuricemia treatment) groups. Continuous variables were expressed as mean ± standard deviation (SD) and categorical variables were expressed as number and proportion; between-group differences were analyzed by Student’s t test or χ² analysis as appropriate. Serum UA levels were divided into quartile groups and between-group differences in BPs were evaluated. Logistic regression analysis was used to evaluate the association between anti-hyperuricemia treatment and prevalent composite CVD. Statistical analysis was conducted in SPSS 18.0 (SPSS Inc., Chicago, USA).
Results

Comparisons of baseline characteristics

A total of 458 hypertensive patients with documented hyperuricemia or with anti-hyperuricemia treatment were screened and finally 346 patients were enrolled (Figure 1). Baseline characteristics were compared between these two groups. As presented in Table I, compared to the anti-hyperuricemia group, patients in the control group had significantly higher serum C-reactive protein (10.6 ±2.8 vs. 7.4 ±1.2 mg/dl) and UA levels (438 ±33 vs. 379 ±64 μmol/l) but lower GFR (76.6 ±10.2 vs. 80.9 ±11.4 ml/min/1.73 m²). In addition, patients in the control group were more likely to receive β-blocker (34.2% vs. 31.1%) and calcium channel blocker treatment (49.2% vs. 43.4%), resulting in a higher mean number of anti-hypertensive medications used in the control group (2.7 ±0.6 vs. 2.1 ±0.7). The prevalence of ischemic stroke was also higher in the control group (15.8% vs. 11.3%). Furthermore, compared to the anti-hyperuricemia group, SBP (133 ±15 vs. 128 ±13 mm Hg), PP (56 ±12 vs. 50 ±10 mm Hg) and heart rate (80 ±14 vs. 72 ±12 beat per minute) were also significantly higher in the control group. No differences in other comorbidities were observed.

Comparisons of BPs among different serum UA level groups

Patients were divided into four groups according to the quartile serum UA levels. As presented in Table II, a linear trend was observed between serum UA level and BP levels. Compared to other groups, SBP, DBP, PP and heart rate were all significantly higher in patients of the 4th quartile serum UA level group.

Association of anti-hyperuricemia treatment and composite CVD

In order to evaluate the association of anti-hyperuricemia treatment and composite CVD, logistic regression analysis was performed. As presented in Table III, in the unadjusted model, anti-hyperuricemia treatment was significantly associated with reduced odds ratio (OR) of composite CVD. After adjusting for potential covariates, in model 4, the OR of anti-hyperuricemia treatment for composite CVD was 0.89 with a 95% confidence interval (IC) of 0.82–0.98. The associations of anti-hyperuricemia treatment and ischemic stroke were also statistically significant with OR = 0.93 and 95% CI: 0.88–0.99, while the associations of anti-hyperuricemia treatment and coronary heart disease and heart failure attenuated into statistical insignificance after adjusting for covariates.

Discussion

Hypertension is a major public health burden around the world including China [19, 20]. Many clinical trials have been conducted to evaluate how to better reduce hypertension-related cardiovascular events. Indeed, more aggressive BP reduction (in terms of therapeutic SBP < 120 mm Hg vs. < 140 mm Hg) were associated with lower cardiovascular events as demonstrated by the SPRINT trial [8]. However, observational studies have consistently shown that a proportion of hypertensive patients with increased serum UA level had more cardiovascular events than their hypertensive counterparts with a normal UA level. For example, Alderman et al. [11] reported that among 7978 moderate-severe hypertensive patients, despite BP control, increased serum UA level was significantly and directly associated with cardiovascular events. In another cohort study, Fang et al. [13] reported that baseline serum UA was independently associated with cardiovascular mortality. In a recent prospective study, Kuwabara et al. [21] also demonstrated that increased serum UA level was associated with higher incidence of hypertension among patients with pre-hypertensive status. These findings together strongly indicate that increased serum UA level not only contributed to risk factor development but also was significantly associated with cardiovascular events. Consistent with prior reports, this study also suggested that in the Chinese hypertensive patients, those with higher serum UA level were more likely to have higher BP levels. The underlying mechanisms might be multifactorial. Prior studies have shown that increased serum UA led to endothelial dysfunction, inflammation, oxidative stress and smooth muscle proliferation, together resulting in reduced nitric oxide production, arterial stiffness and BP elevation [22–26].
Table I. Comparisons of baseline characteristics

| Variables                                | Anti-hyperuricemia group (n = 106) | Control group (n = 240) |
|------------------------------------------|------------------------------------|-------------------------|
| Age [years]                              | 50.8 ±16.7                         | 52.4 ±13.5              |
| Female, n (%)                            | 30 (28.3)                          | 66 (27.5)               |
| Smoker, n (%)                            | 37 (34.9)                          | 80 (33.3)               |
| Body mass index [kg/m²]                  | 24.5 ±4.3                          | 25.0 ±4.9               |
| Diabetes mellitus, n (%)                 | 20 (18.9)                          | 45 (18.8)               |
| C-reactive protein [mg/dl]               | 7.4 ±1.2                           | 10.6 ±2.8*              |
| Total cholesterol [mmol/l]               | 4.8 ±0.7                           | 5.0 ±0.8                |
| Fasting plasma glucose [mmol/l]          | 6.0 ±0.5                           | 6.2 ±0.8                |
| Uric acid [μmol/l]                       | 379 ±64                            | 438 ±33*                |
| Creatinine [μmol/l]                      | 76.4 ±21.3                         | 79.2 ±20.6              |
| Glomerular filtration rate [ml/min/1.73 m²] | 80.9 ±11.4                        | 76.6 ±10.2*             |
| Statin, n (%)                            | 29 (27.4)                          | 70 (29.2)               |

Anti-hypertensive medications, n (%):

| Medications                      | Anti-hyperuricemia group (n = 106) | Control group (n = 240) |
|----------------------------------|------------------------------------|-------------------------|
| Hydrochlorothiazide              | 35 (33.0)                          | 78 (32.5)               |
| ACEI/ARB                         | 40 (37.7)                          | 87 (36.3)               |
| β-Blocker                        | 33 (31.1)                          | 82 (34.2)*              |
| Calcium channel blocker          | 46 (43.4)                          | 118 (49.2)*             |

| Statin, n (%)                     | 29 (27.4)                          | 70 (29.2)               |

Hypoglycemia medications, n (%):

| Medications                      | Anti-hyperuricemia group (n = 106) | Control group (n = 240) |
|----------------------------------|------------------------------------|-------------------------|

| Composite CVD, n (%):            |                                    |                         |
| Coronary heart disease           | 7 (6.6)                            | 17 (7.1)                |
| Ischemic stroke                  | 12 (11.3)                          | 38 (15.8)*              |
| Heart failure                    | 5 (4.7)                            | 13 (5.4)                |

Systolic blood pressure [mm Hg]

| Anti-hyperuricemia group (n = 106) | Control group (n = 240) |
|-----------------------------------|-------------------------|
| 1st quartile (n = 86)             | 124 ±14                 | 65 ±8                   |
| 2nd quartile (n = 86)             | 133 ±13                 | 71 ±12                  |
| 3rd quartile (n = 87)             | 141 ±16                 | 75 ±10                  |
| 4th quartile (n = 87)             | 154 ±20*                | 80 ±12*                 |

Diastolic blood pressure [mm Hg]

| Anti-hyperuricemia group (n = 106) | Control group (n = 240) |
|-----------------------------------|-------------------------|
| 1st quartile (n = 86)             | 65 ±8                   | 45 ±8                   |
| 2nd quartile (n = 86)             | 71 ±12                  | 49 ±7                   |
| 3rd quartile (n = 87)             | 75 ±10                  | 55 ±9                   |
| 4th quartile (n = 87)             | 80 ±12*                 | 60 ±12*                 |

Pulse pressure [mm Hg]

| Anti-hyperuricemia group (n = 106) | Control group (n = 240) |
|-----------------------------------|-------------------------|
| 1st quartile (n = 86)             | 45 ±8                   | 67 ±9                   |
| 2nd quartile (n = 86)             | 49 ±7                   | 74 ±11                  |
| 3rd quartile (n = 87)             | 55 ±9                   | 80 ±10                  |
| 4th quartile (n = 87)             | 60 ±12*                 | 86 ±16*                 |

Table II. Blood pressure comparisons between different serum UA levels

| UA levels | SBP [mm Hg] | DBP [mm Hg] | PP [mm Hg] | HR [bpm]  |
|-----------|-------------|-------------|------------|-----------|
| 1st quartile (n = 86) | 124 ±14     | 65 ±8       | 45 ±8      | 67 ±9     |
| 2nd quartile (n = 86) | 133 ±13     | 71 ±12      | 49 ±7      | 74 ±11    |
| 3rd quartile (n = 87) | 141 ±16     | 75 ±10      | 55 ±9      | 80 ±10    |
| 4th quartile (n = 87) | 154 ±20*    | 80 ±12*     | 60 ±12*    | 86 ±16*   |

P < 0.05 versus other groups; UA – uric acid, SBP – systolic blood pressure, DBP – diastolic blood pressure, PP – pulse pressure, HR – heart rate, bpm – beats per minute.
Unfortunately, to our knowledge, up till now, no clinical trials have demonstrated that lowering serum UA level can improve cardiovascular prognosis of hypertensive patients. This cross-sectional study indicated that in hypertensive patients with increased serum UA level, allopurinol treatment was associated with lower prevalence of composite CVD, and these benefits were mainly driven by lower risk of ischemic stroke. To our knowledge, this was the first study to show that allopurinol treatment was associated with lower risk of ischemic stroke in Chinese hypertensive patients. Notably, the incidence and prevalence of ischemic stroke were significantly higher than those of other atherosclerotic cardiovascular diseases [19]. The underlying mechanism might involve the effects of allopurinol to reduce serum UA level, which in turn led to a reduced inflammatory reaction. Indeed, compared to the control group, serum C-reactive protein level was significantly lower in the anti-hyperuricemia group. These findings suggest that in Chinese hypertensive patients, screening serum UA level and treatment of hyperuricemia may provide great opportunities in reducing CVD burden in China. Further studies are needed to corroborate our findings. In addition, whether findings from this study can extrapolate to other ethnic populations also needs to be evaluated.

Some limitations of this study should be addressed. First of all, the inherent bias of observational study did not allow us to prove a causal relationship between anti-hyperuricemia treatment and risk of prevalent CVD. However, findings from this study provide insight into the association of anti-hyperuricemia treatment and risk of prevalent CVD. Second, this study was conducted in Chinese hypertensive patients and future studies in other ethnic groups are needed to corroborate our findings. Third, although we have adjusted for potential confounding factors, unmeasured and undetected factors still existed which may influence the association of anti-hyperuricemia treatment and risk of prevalent CVD. Last but not least, results from an observational study cannot substitute for a randomized clinical trial, and the clinical relevance of our findings is in providing more evidence to support the notion that reducing serum UA level should be beneficial for prevention of cardiovascular events.

The major findings of this study were as follows: 1) compared to the control group, patients in the anti-hyperuricemia treatment group had lower prevalence of composite CVD, which was mainly driven by the differences in prevalent ischemic stroke; 2) patients with higher serum UA level were more likely to have higher BP levels; 3) anti-hyperuricemia treatment was significantly associated with lower risk of prevalent CVD after adjusting for confounding factors. These findings together indicate that hypertensive patients with hyperuricemia have higher risk of CVD and anti-hyperuricemia treatment may be beneficial for reducing the risk of CVD. Future studies are needed to corroborate our findings.

In conclusion, our preliminary study indicates that in primary hypertensive patients, increased serum UA level is associated with higher BP level. Furthermore, anti-hyperuricemia treatment is associated with lower prevalence of CVD. Randomized controlled trials are warranted to evaluate whether reducing UA level can improve prognosis of patients with hyperuricemia.

Acknowledgments

The current study was supported by a grant from Shenzhen Science and Technology Innovation Committee (JCYJ20160427174117767).

Conflict of interest

The authors declare no conflict of interest.

References

1. Staessen JA, Gasowski J, Wang JG, et al. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet 2000; 355: 865-72.
2. Salles GF, Leite NC, Pereira BB, Nascimento EM, Cardoso CR. Prognostic impact of clinic and ambulatory blood pressure components in high-risk type 2 diabetic patients: the Rio de Janeiro Type 2 Diabetes Cohort Study. J Hypertens 2013; 31: 2176-86.

3. Cal A, Zhong Q, Liu C, et al. Associations of systolic and diastolic blood pressure night-to-day ratios with atherosclerotic cardiovascular diseases. Hypertens Res 2016; 39: 874-8.

4. Gomari-Boukhatem H, Bouchoiuca A, Mekki K, Chenil K, Belhaj M, Bouchenak M. Blood pressure, dyslipidemia and inflammatory factors are related to body mass index in scholar adolescents. Arch Med Sci 2017; 13: 46-52.

5. Aronow WS. Lifestyle measures for treating hypertension. Arch Med Sci 2017; 13: 1241-3.

6. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of inorganic nitrate and allopurinol in renovascular hypertension 2000; 36: 1072-8.

7. Thomopoulos C, Parati G, Zanchetti A. Effects of blood-pressure-lowering treatment on outcome incidence in hypertension: 10 – Should blood pressure management differ in hypertensive patients with and without diabetes mellitus? Overview and meta-analyses of randomized trials. J Hypertens 2017; 35: 922-44.

8. SPRINT Research Group, Wright JT Jr, Williamson JD, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 2015; 373: 2103-16.

9. Messerli FH, Frohlich ED, Dreslinski GR, Suarez DH, Arsimmujo GG. Serum uric acid in essential hypertension: an indicator of renal vascular involvement. Ann Intern Med 1980; 93: 817-21.

10. Shankar A, Klein R, Klein BE, Nieto FJ. The association between serum uric acid level and long-term incidence of hypertension: population-based cohort study. J Hum Hypertens 2006; 20: 937-45.

11. Alderman MH, Cohen H, Madhavan S, Kivlighn S. Serum uric acid and cardiovascular events in successfully treated hypertensive patients. Hypertension 1999; 34: 144-50.

12. Culleton BF, Larson MG, Kannel WB, Levy D. Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med 1999; 131: 7-13.

13. Fang J, Alderman MH. Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey. JAMA 2000; 283: 2404-10.

14. Verdecchia P, Schilliaci G, Reboldi G, Santeusanio F, Porcellati C, Brunetti P. Relation between serum uric acid and risk of cardiovascular disease in essential hypertension. The PIUMA study. Hypertension 2000; 36: 1072-8.

15. Essawy SS, Abdel-Sater KA, Elbaz AA. Comparing the effects of inorganic nitrate and allopurinol in renovascular complications of metabolic syndrome in rats: role of nitrergic oxide and uric acid. Arch Med Sci 2014; 10: 537-45.

16. Viaggi F, Parodi D, Leoncini G, et al. Serum uric acid and target organ damage in primary hypertension. Hypertension 2005; 45: 991-6.

17. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2003; 39 (2 Suppl 1): S1-266.

18. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension 2018; 71: 1269-324.

19. Su L, Sun L, Xu L. Review on the prevalence, risk factors and disease. Management of hypertension among floating population in China during 1990-2016. Glob Health Res Policy 2018; 3: 24.

20. Lu J, Lu Y, Wang X, et al. Prevalence, awareness, treatment, and control of hypertension in China: data from 1.7 million adults in a population-based screening study (China PEACE Million Persons Project). Lancet 2017; 390: 2549-58.

21. Kuwabara M, Hisatome I, Niwa K, et al. Uric acid is a strong risk marker for developing hypertension from prehypertension: a 5-year Japanese cohort study. Hypertension 2018; 71: 78-86.

22. Kuwabara M, Kanbay M, Hisatome I. Uric acid and hypertension because of arterial stiffness. Hypertension 2018; 72: 582-4.

23. Bavishi C, Messerli FH, Romoldi SF. Serum uric acid in primary hypertension: from innocent bystander to primum movens. Hypertension 2016; 67: 845-7.

24. Kanellis J, Watanabe S, Li JH, et al. Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and cyclooxygenase-2. Hypertension 2003; 41: 1287-93.

25. Kanabrocki EL, Third JL, Ryan MD, et al. Circadian relationship of serum uric acid and nitric oxide. JAMA 2000; 283: 2240-1.

26. Shalaby MM, Sobeih AA, Abdulghany WE, Behiry EG, Ismail YM, Abd-El-Aziz MA. Mean platelet volume and serum uric acid in neonatal sepsis: a case-control study. Ann Med Surg (Lond) 2017; 20: 97-102.